Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M.

J Clin Oncol. 2010 May 20;28(15):2505-11. doi: 10.1200/JCO.2009.25.1082. Epub 2010 Apr 20.

PMID:
20406939
2.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
3.

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.

Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, Rapaport B, Frank TS, Nafa K, Ellis NA, Parmigiani G, Offit K.

J Med Genet. 2002 Aug;39(8):611-4. No abstract available.

4.

Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.

Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.

Breast Cancer Res Treat. 2006 Jan;95(1):81-7. Epub 2005 Oct 27.

PMID:
16261400
5.

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.

Cancer. 2005 Dec 15;104(12):2807-16.

6.
7.

Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.

Kim YT, Nam EJ, Yoon BS, Kim SW, Kim SH, Kim JH, Kim HK, Koo JS, Kim JW.

Gynecol Oncol. 2005 Dec;99(3):585-90. Epub 2005 Aug 9.

PMID:
16084575
8.

Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.

Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC.

J Med Genet. 2005 Mar;42(3):e20. Review. No abstract available.

9.

Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report.

Koul A, Loman N, Malander S, Borg A, Ridderheim M.

Gynecol Oncol. 2001 Mar;80(3):399-402.

PMID:
11263939
10.

BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.

Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, Pereira D, Rodrigues H, Bento MJ, Fráguas A, Moura G, Regateiro F, Castedo S, Teixeira MR.

Fam Cancer. 2006;5(4):379-87. Epub 2006 Jul 7.

PMID:
16826315
11.

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J.

Gynecol Oncol. 2008 Feb;108(2):433-7. Epub 2007 Nov 7.

PMID:
17997147
12.

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA.

Gynecol Oncol. 2005 Jan;96(1):222-6.

PMID:
15589605
13.

Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.

Elit L, Baigal G, Jack E, Munkhtaivan A, Narod SA.

Eur J Gynaecol Oncol. 2002;23(5):397-400.

PMID:
12440810
14.

Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.

Reedy M, Gallion H, Fowler JM, Kryscio R, Smith SA.

Gynecol Oncol. 2002 May;85(2):255-9.

PMID:
11972384
15.

Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.

Swisher E.

Curr Womens Health Rep. 2003 Feb;3(1):27-32. Review.

PMID:
12521547
16.

Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany.

Hamann U, Liu X, Lange S, Ulmer HU, Benner A, Scott RJ.

J Med Genet. 2002 Mar;39(3):E12. No abstract available.

17.

BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.

Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.

J Biosci. 2009 Sep;34(3):415-22.

18.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.; Australian Ovarian Cancer Study Management Group..

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
19.

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.

Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah P, Lane G, Ponder B, Bishop DT, Easton DF.

Clin Cancer Res. 2004 Apr 1;10(7):2473-81.

20.

A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.

Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, Martinsson T, Wahlström J, Karlsson P, Nordling M.

Fam Cancer. 2005;4(2):89-96.

PMID:
15951958

Supplemental Content

Support Center